DISPATCHES FROM INTERPHEX
Patheon and DSM crossover limited, more growth targeted says DPx
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.